Introduction: The zoledronic acid, increases the QoL, pain diminution and a survival increment in patients with breast cancer and multiple myeloma, due to its analgesic and protective effect upon diminishing the events of pathological fractures.
Objectives: To evaluate the efficiency of the tratment with Zometa in outpatient condition, to all the assembly of patients with breast, prostate cancer and myeloma in 3 consecutive administrations, as well as evaluating the changes in the QoL and consumption of analgesics.
Material and Methods: Prospective study on 68 consecutive patients treated with ac.zoledronic evaluated by means of questionnaires such as BPI and EuroQoL-5D during June-August of 2003.
Results: 80% of the patients with IK>70.61% breast, 33% myeloma and 6% prostate.The basal analgesia used according to the WHO scale it is of 31-35% for the first stage in breast cancer and myeloma, 52 -43 -50% on second stage for breast, myeloma, prostate and 17-21-50% at the third stage for breast, myeloma and prostate. Presence of 20%, 30% and 58% of visceral, somatic and neuropathic pain. VAS average of 4.6 in breast, 4.9 in myeloma and 6.0 in prostate. Patient understanding difficulties when detected with the BPI. Reliability and high clinical correlation: symptomatic and emotional sphere with the EuroQol-5D after an interin analysis. Symptomatic adjustement with answer>80%.
Conclusions: The questionnaires employed allow us to evaluate and detect clinical problems and of emotional sphere very quick although the BPI instrument would be more useful within the investigational sphere. The generic EuroQoL-5D is a "screening" tool exempt from difficult interpretations for the majority of patients in outpatient conditions.